MediWound Ltd. (MDWD) Research

MediWound Ltd., an Israeli biopharmaceutical company established in 2000 and based in Yavne, focuses on the innovation, production, and sale of advanced biological treatments for the healing and regrowth of damaged tissues. The company's key commercialized product is NexoBrid, a biological drug distributed to specialized burn centers and hospital burn units. NexoBrid is specifically formulated for the enzymatic debridement of eschar—dead or compromised tissue—in adults suffering from severe thermal burns, encompassing deep partial-thickness and full-thickness injuries. Furthermore, MediWound's development pipeline includes EscharEx, which has successfully concluded Phase II clinical trials for addressing chronic and other intractable wounds. Another investigational therapy, MW005, is currently undergoing Phase I/II clinical studies for the treatment of low-risk basal cell carcinoma.

Market snapshot

Symbol
MDWD
Price
$14.24
Day change
+0.28%
Market cap
$154.7M
P/E ratio
-7.02x
52-week range
13.54-21.255
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$27.00

Peer companies

  • Aardvark Therapeutics, Inc. Common Stock (AARD)
  • Eupraxia Pharmaceuticals Inc. (EPRX)
  • Genfit S.A. (GNFT)
  • Inventiva S.A. (IVA)
  • Invivyd, Inc. (IVVD)
  • Neonc Technologies Holdings, Inc. (NTHI)
  • Orchestra BioMed Holdings, Inc. (OBIO)
  • Cartesian Therapeutics, Inc. (RNAC)

Recent insider activity

  • SHAMIR NACHUM — P-Purchase (5825 shares) on 2026-06-03
  • SHAMIR NACHUM — P-Purchase (175 shares) on 2026-06-03
  • Fox David Morton — P-Purchase (1797 shares) on 2026-06-01
  • Fox David Morton — P-Purchase (10 shares) on 2026-06-01
  • Fox David Morton — P-Purchase (1730 shares) on 2026-06-01

Open MediWound Ltd. (MDWD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.